Viridian Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held on June 3, 2021. Viridian Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Boulder, CO. The company's common stock trades on The Nasdaq Stock Market under the symbol VRDN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
On the record date of April 15, 2021, there were 7,231,370 shares of common stock issued and outstanding. Stockholders voted on the following proposals:
- Proposal 1 (Election of Directors): All four nominees (Peter Harwin, Tomas Kiselak, Arlene M. Morris, and Jonathan Violin) received significant support, with over 5 million votes "For" each.
- Proposal 2 (Ratification of Auditors): KPMG LLP was ratified as the independent registered public accounting firm for 2021 with 5,817,420 votes "For".
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation passed with 5,031,016 votes "For".
- Proposal 4 (Board Classification): The vote to amend the certificate of incorporation to classify the Board into three staggered classes was not finalized. The meeting was adjourned to allow additional time for voting.
Outlook, Risks, and Unusual Items
The meeting was adjourned and reconvened for June 11, 2021, at 10:00 a.m. Mountain Time. The sole purpose of the reconvened meeting is to allow additional time for stockholders to vote on Proposal 4 regarding the classification of the Board of Directors. The reconvened meeting will be held virtually.
Key Facts for Investor Verification
- Verify the outcome of Proposal 4 (Board Classification) at the reconvened meeting on June 11, 2021.
- Confirm the total number of shares outstanding remains 7,231,370 or has changed since the April 15 record date.
- Review the company's financial statements in the most recent 10-K or 10-Q for revenue and cash position data, as this 8-K contains no financial metrics.